ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $77.05, for a total transaction of $96,312.50. Following the transaction, the chief financial officer now directly owns 64,691 shares in the company, valued at approximately $4,984,441.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Brett Sandercock also recently made the following trade(s):

  • On Friday, September 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $77.56, for a total transaction of $96,950.00.
  • On Tuesday, August 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $77.49, for a total transaction of $96,862.50.

ResMed Inc. (RMD) opened at 76.53 on Wednesday. The stock has a 50 day moving average of $76.76 and a 200-day moving average of $73.89. ResMed Inc. has a 52 week low of $56.59 and a 52 week high of $81.87. The firm has a market cap of $10.88 billion, a PE ratio of 31.89 and a beta of 0.77.

ResMed (NYSE:RMD) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.02. The company had revenue of $556.69 million for the quarter, compared to analyst estimates of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 earnings per share. Analysts expect that ResMed Inc. will post $3.05 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 21st. Investors of record on Thursday, August 17th were paid a $0.35 dividend. The ex-dividend date was Tuesday, August 15th. This is an increase from ResMed’s previous quarterly dividend of $0.33. This represents a $1.40 annualized dividend and a yield of 1.83%. ResMed’s payout ratio is 58.09%.

COPYRIGHT VIOLATION NOTICE: “ResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 Shares” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/resmed-inc-rmd-cfo-brett-sandercock-sells-1250-shares/1607220.html.

Several analysts have issued reports on RMD shares. Zacks Investment Research upgraded shares of ResMed from a “sell” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group lowered shares of ResMed from an “outperform” rating to a “neutral” rating in a research report on Tuesday, August 8th. Citigroup Inc. raised shares of ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 2nd. BMO Capital Markets increased their target price on shares of ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research note on Wednesday, August 2nd. Finally, Bank of America Corporation cut shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $68.50.

Hedge funds have recently bought and sold shares of the business. YorkBridge Wealth Partners LLC lifted its holdings in shares of ResMed by 4.9% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 69 shares in the last quarter. Creative Planning boosted its position in shares of ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock valued at $130,000 after acquiring an additional 823 shares during the period. Toronto Dominion Bank boosted its position in shares of ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 197 shares during the period. Van ECK Associates Corp boosted its position in shares of ResMed by 7.5% in the first quarter. Van ECK Associates Corp now owns 1,945 shares of the medical equipment provider’s stock valued at $140,000 after acquiring an additional 136 shares during the period. Finally, Huntington National Bank bought a new stake in shares of ResMed in the second quarter valued at about $156,000. Hedge funds and other institutional investors own 60.10% of the company’s stock.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.